| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 23.9 | 31.4 | 19.1 |
| Other income | 5.8 | -0.2 | 11.9 |
| Total income | 29.7 | 31.2 | 31.1 |
| Profit before exceptional items & tax | 1.0 | 3.1 | 11.8 |
| Profit before tax | 1.0 | 3.1 | 11.8 |
| Net profit | 1.0 | 1.4 | 11.8 |
| Operating margin | 3.4% | 9.9% | 37.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -91.50% |
|---|---|
| Net profit, quarter on quarter | -28.60% |
| Revenue, year on year | +25.10% |
| Operating profit, year on year | -4700.00% |
| Operating profit, quarter on quarter | -245.50% |
BSE results filing, NSE: ALPA. Figures extracted from the filing.
Alpa Laboratories Ltd: key numbers
- Share price
- ₹57.41
- Market cap
- ₹120.8 Cr
- Revenue (annual)
- ₹105.8 Cr
- Net profit (annual)
- ₹15.01 Cr
- P/E (TTM)
- 34.6×Sector 43.8×
- Promoter holding
- 57.19%+0.00% QoQ
- FII holding
- 0.35%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alpa Laboratories Ltd
All →Alpa Laboratories Board Meeting Date
ALPA Laboratories Limited has intimated a board meeting on 14 November 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. Trading window is closed from 1 October 2026 until 48 hours after results announcement.
Alpa Laboratories Other Announcement
Alpa Laboratories filed its quarterly shareholding pattern for the period ended 30 September 2026 under Regulation 31(1)(b). This is a periodic statutory disclosure with no transaction.
Alpa Laboratories Other Announcement
Alpa Laboratories Ltd has submitted its quarterly shareholding pattern under Regulation 31(1)(b) of the SEBI Listing Regulations for the period ended September 30, 2026.
Alpa Laboratories Annual General Meeting
Alpa Laboratories shareholders approved seven resolutions at the AGM, including a Rs. 160 Crore limit for loans and investments. All ordinary and special resolutions were passed.
- Value
- ₹160.0 Cr
Alpa Laboratories Annual General Meeting
Alpa Laboratories Ltd. held its 38th AGM on September 30, 2026. Shareholders approved financial statements, director appointments, auditor remuneration, and investment limits under Section 186.
Alpa Laboratories Management Change
Alpa Laboratories Ltd has appointed Ms. Diksha Jaswani as the Company Secretary and Compliance Officer (KMP), effective September 17, 2026.